Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Hyper-IgE syndrome Indication Strategy Report 2026: STAT3, Trials and Deals
24 July 2026
2026 Hyper-IgE syndrome strategy: epidemiology, STAT3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Wiskott-Aldrich syndrome Indication Strategy Report 2026: WAS, Trials and Deals
24 July 2026
2026 Wiskott-Aldrich syndrome strategy: epidemiology, WAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
ADA-SCID Indication Strategy Report 2026: ADA, Trials and Deals
24 July 2026
2026 ADA-SCID strategy: epidemiology, ADA biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Latest Hotspot
8 min read
Chronic granulomatous disease Indication Strategy Report 2026: NOX2, Trials and Deals
24 July 2026
2026 Chronic granulomatous disease strategy: epidemiology, NOX2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Severe combined immunodeficiency Indication Strategy Report 2026: IL2RG, Trials and Deals
24 July 2026
2026 Severe combined immunodeficiency strategy: epidemiology, IL2RG biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Common variable immunodeficiency Indication Strategy Report 2026: BAFF-R, Trials and Deals
24 July 2026
2026 Common variable immunodeficiency strategy: epidemiology, BAFF-R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
X-linked agammaglobulinemia Indication Strategy Report 2026: BTK, Trials and Deals
24 July 2026
2026 X-linked agammaglobulinemia strategy: epidemiology, BTK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Activated PI3K-delta syndrome Indication Strategy Report 2026: PI3K-delta, Trials and Deals
24 July 2026
2026 Activated PI3K-delta syndrome strategy: epidemiology, PI3K-delta biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
IPEX syndrome Indication Strategy Report 2026: FOXP3, Trials and Deals
24 July 2026
2026 IPEX syndrome strategy: epidemiology, FOXP3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Macrophage activation syndrome Indication Strategy Report 2026: IFN-gamma, Trials and Deals
24 July 2026
2026 Macrophage activation syndrome strategy: epidemiology, IFN-gamma biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Autoimmune lymphoproliferative syndrome Indication Strategy Report 2026: FAS, Trials and Deals
24 July 2026
2026 Autoimmune lymphoproliferative syndrome strategy: epidemiology, FAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hemophagocytic lymphohistiocytosis Indication Strategy Report 2026: IFN-gamma, Trials and Deals
24 July 2026
2026 Hemophagocytic lymphohistiocytosis strategy: epidemiology, IFN-gamma biology, clinical competition, recent deals, unmet need and market attractiveness.